The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

Autor: Bridges, K., Telfer, M., Ataga, Kenneth, Orringer, E., Hoehner, C., Hernandez, S., Valdez, S., Temple, D., Shurin, S., Johnson-Telfair, A., Hagar, W., Vichinsky, E., Smith, Wally, Steinberg, Martin H., Kleman, K., Rosse, W., Waller, L., Barber, Y., Chow, J., Gascon, P., Winograd, C., Di Paolo, P., Hui, M., Moshang, J., Olivieri, N., Dorn, L., Siteman, J., Embury, S., Eckman, J., Ballas, Samir K., Anderson, A., White, L., Harrington, T., Talischy-Zahed, N., Shaw, D., Scott, B., Waclawiw, Myron A., Labrousse, W., Adler, B., Phillips, G., Bigelow, C., Armstrong, F. Danny, Chiarucci, K., Childerie, S., McLaughlin, K., Mandell, E., DeCastro, Laura, Claster, S., Knors, V., Gargiulo, S., Jones, S., Tynan, B., Saunthararajah, Y., Saunders, T., Maddox, B., Hackney-Stevens, E., Keverline, L., Gardner, D., Carter-Randall, E., Schmidt, B., Tracy, A., Davies, D., Carlos, T., Kutlar, Abdullah, Finke, H., Nwokolo, C., Perlin, E., Onyekwere, O. C., Okam, M., Peace, D., Milner, P., Koshy, M., Sheikhai, M., Daitch, L., Swerdlow, Paul, Pendarvis, G., Harrell, R., Case, E., Brenner, A., Bailey, J. H., Strayhorn, D., Prchal, J., Ramirez, G., Dosik, H., Platt, A., McGee, M., Lewis, N., Castro, Oswaldo, Palmer, A., Wilkes, E., Braddock, J., Sabahi, V., Pegelow, C., Bellevue, R., McArdle, T., O'Brien, R., Williams, K., Usry, L., Eskridge, L., Berman, B., Allen, G. E., Earles, A., Bryan, M., Davis, A., Rodriguez, E. M., Souffrant, H., Genther, K., McCarthy, William F., Roundtree-Schmotzer, A., Ryans, P.

A randomized, controlled clinical trial established the efficacy and safety of short-term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long-term hydroxyurea usage, patients in this trial were followed for 17.5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43f4a9c09122d8022b7db612076af118